Current Role of Lamivudine Regarding Therapeutic Response and Resistance in Children with Chronic Hepatitis B |
Hong, Suk Jin
(Department of Pediatrics, Kyungpook National University School of Medicine)
Kim, Yeo Hyang (Department of Pediatrics, Kyungpook National University School of Medicine) Choe, Byung-Ho (Department of Pediatrics, Kyungpook National University School of Medicine) Park, Hyo Jung (Department of Pediatrics, Kyungpook National University School of Medicine) Tak, Won-Young (Department of Internal Medicine, Kyungpook National University School of Medicine) Kweon, Young-Oh (Department of Internal Medicine, Kyungpook National University School of Medicine) |
1 | Bortolotti F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10. DOI |
2 | Conjeevaram HS, Di Bisceglie AM. Management of chronic viral hepatitis in children. J Pediatr Gastroenterol Nutr 1995;20:365-75. DOI |
3 | Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63. DOI |
4 | Choe BH, Lee JH, Jang YC, Jang CH, Oh KW, Kwon S, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-8. DOI |
5 | Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J 2004;23:441-5. DOI |
6 | Liberek A, Szaflarska-Poplawska A, Korzon M, Luczak G, Gora-Gebka M, Los-Rycharska E, et al. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006;12:2412-6. DOI |
7 | Park NH, Shin JW, Park JH, Bang SJ, Kim DY, Joo KR, et al. Predictive factors and efficacy of lamivudine treatment in chronic hepatitis B infection. Korean J Gastroenterol 2003;42:303-12. |
8 | Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al; Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32. DOI |
9 | Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005;48:341-9. DOI |
10 | Hartman C, Berkowitz D, Eshach-Adiv O, Hino B, Rimon N, Satinger I, et al. Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006;43:494-8. DOI |
11 | Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32. DOI |
12 | Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al; International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13. DOI |
13 | Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114:988-95. DOI |
14 | Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34. DOI |
15 | Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6. DOI |
16 | Hong SP, Han KH, Ahn SH, Paik YH, Moon BS, Chon CY, et al. Long-term efficacy and durability of lamivudine therapy in patients with chronic hepatitis B. Korean J Hepatol 2001;7:423-31. |
17 | Dikici B, Ozgenc F, Kalayci AG, Targan S, Ozkan T, Selimoglu A, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004;19:127-33. DOI |
18 | Broderick A, Jonas MM. Management of hepatitis B in children. Clin Liver Dis 2004;8:387-401. DOI |
19 | Kim JM, Choe BH, Chu MA, Cho SM. Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B. Korean J Hepatol 2009;15:168-78. DOI |
20 | Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, Bujnowska A, Mozer-Lisewska I, Słuzewski W. Efficacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res 2005;31:217-22. DOI |
21 | Dikici B, Ece A, Bosnak M. Which combination should be preferred in the management of children with chronic hepatitis B infection? J Clin Gastroenterol 2005;39:745-6. DOI |
22 | Ozgenc F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004;9:729-32. |
23 | Choe BH, Kim JM, Lee JH, Jang YC, Jang CH, Oh KW, et al. Lamivudine treatment in children with chronic hepatitis B: long-term therapeutic Response, optimal duration and resistance. the 39th Annual Meeting of ESPGHAN; 2006; Dresden, Germany. J Pediatr Gastroenterol Nutr 2006:E64-5. |
24 | Hong SJ, Choe BH. Strategy to overcome drug resistance that develops during treatment of chronic hepatitis b in children. Pediatr Gastroenterol Hepatol Nutr 2012;15:63-73. DOI |
25 | Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr 2012;55:648-52. DOI |